清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumour Malignancies

嵌合抗原受体 抗原 T细胞 CD28 CD19 免疫疗法 癌症免疫疗法 CD3型 生物 免疫学 病毒学 癌症研究 医学 分子生物学 CD8型 免疫系统
作者
Ιωάννα Λαζανά,Emmanouil Simantirakis,Dimitris E. Ioannou,Vaggelis Kourous,Panayiota Fotopoulou,George Vassilopoulos
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 12697-12698
标识
DOI:10.1182/blood-2022-165048
摘要

Introduction Chimeric antigen receptor (CAR) T cells have transformed the field of cancer immunotherapy. Other approaches, such as the use of Fc gamma chimeric receptor (Fcγ-CR)-T cells have further expanded the applicability of such therapies in both solid and liquid tumours with the added benefit of tackling some of the hurdles associated with CAR-T therapies (such as loss or down-regulation of the target antigen). Previous studies have generated Fcγ-CR-T cells from autologous cells, which carry several limitations (prolonged production time, costly, manufacturing failure), whereas the use of Lentiviral vectors (LV) is endowed with extra limitations (packaging limits and mutagenesis risk). Our group has developed an in-house Fcγ-CR-T cell product, using a safer to LV, foamy virus (FV) vector and T cells from healthy donors. Materials We constructed FV vectors expressing the CD16 V158, which has higher Fc binding and is associated with higher tumour killing, the T cell stimulatory molecule CD3ζ and the costimulatory molecule CD28 and an EFP1a promoter. 2nd generation LV vector backbones were purchased from a commercial vendor. Peripheral blood from healthy individuals were used as T cell sources. T cells were activated by anti-CD3/CD28 beads and transduced with CD16-CR, LV or FV vectors. Transduction efficiency was assayed by flow cytometry (FCM) using an anti-CD16 antibody (Ab), on day 3. The human cell lines Raji, Panc01 and DLD-1 were used for functional assays, in the presence of the Abs Rituximab (anti-CD20) and Cetuximab (anti-EGFR), respectively, at a concentration of 0.1 ug/ml. The CR's Ab-binding capacity was assessed by incubating the CD16-CRs with the Abs for 30mins, followed by an anti-human Ig PE antibody and the related fluorescence intensity was assessed. To determine whether Ab binding to CD16-CR can promote aggregation of effector and target cells, CFSE-labelled target cells were mixed with Ab-coated CD16-CRs for 60 mins and the formation of CFSE-PE doublets was assessed by FCM. Their cytotoxic effect was evaluated against the CFSE-labelled Raji or DLD-1 or Panc01 cells at different ratios (5:1, 10:1) for 18 hours, in the presence of Rituximab (0.1ug/ml) or Cetuximab (0.1ug/ml), respectively. The % of live cells was assessed by flow cytometry and calculated as: [1-live targets (sample)/live targets (control)]x100. Results LV and FV vector titers were between 3-5x10^6 TU/ml and 4-5x10^6 TU/ml, respectively. Transduction efficiency ranged from 58.3-69.2% with FV vectors (MOI 3-5) and 85.2-85.9% with LV vectors (MOI 10-20). The Ab-binding capacity of FV-CD16-CRs was determined to be 68.7% (SEM 2.3) and 71.3% (SEM 3.1), (n=3) for Rituximab and Cetuximab, respectively, whereas that of LV-CD16-CRs was 72.1 (SEM 3.3) and 76.5 (SEM 2.8), (n=3), respectively. Cell aggregation of effector and target cells, assessed as doublets, was: (i) 32%, 39% and 36% for FV-CD16-CRs and (ii) 26%, 31% and 29% for LV-CD16-CRs, coated with Rituximab and Cetuximab, respectively, and it was specific for the Raji, DLD-1 and Panc01 cells, respectively. Next, we assessed whether CD16-CR T cells were able to kill target cells in the presence of specific antibodies. Results showed that the FV-CD16-CR-induced % cell lysis was: (i) 26.3% and 51.5% at 5:1 and 10:1 ratio, respectively, in the presence of Rituximab and Raji cells, (ii) 41.5% and 57.7% at 5:1 and 10:1 ratio, respectively, in the presence of Cetuximab and DLD1 cells and (iii) 39.4% and 57.3% at 5:1 and 10:1 ratio, respectively, in the presence of Cetuximab and Panc01 cells. For LV-CD16-CRs the respective % lysis was comparable. More importantly, this lysis was shown to be specific (no lysis noted with untransduced T cells) and significantly lower in the absence of the antibodies. Conclusion Our group has developed for the first time a FV vector for the generation of CD16-CR T cells, with an efficient gene transfer to human T cells and with potent in vitro cytotoxic properties, similar to their LV-derived counterpart. Overall, we provide a proof of concept that allogeneic, in-house Fcγ-CR-T cells derived from a non-pathogenic viral backbone such as the FV, could be a safe, efficient and affordable alternative to LV-derived vectors for immunotherapy. Our future aim is to further modify these Fcγ-CR-T cells, by interfering with immune checkpoint molecules, in order to achieve better tumour penetration and tackle the anergy induced by the tumour microenvironment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
怕黑的妖丽完成签到,获得积分10
4秒前
哈哈一呀发布了新的文献求助10
7秒前
勤劳寒松完成签到,获得积分10
36秒前
坚定的咖啡完成签到,获得积分10
54秒前
tlh完成签到 ,获得积分10
58秒前
1分钟前
jiangxiang完成签到,获得积分20
1分钟前
坚定谷蕊完成签到,获得积分10
1分钟前
1分钟前
科研通AI65的应助被jiangxiang采纳,获得10
1分钟前
淡然雅彤完成签到,获得积分10
1分钟前
温柔的海秋完成签到,获得积分10
1分钟前
胡萝卜完成签到,获得积分10
2分钟前
强健的千柔完成签到,获得积分10
2分钟前
懦弱的绿蝶完成签到,获得积分10
2分钟前
闪闪小凡完成签到,获得积分10
2分钟前
Hello的应助被科研通管家采纳,获得10
3分钟前
包容大地完成签到,获得积分10
3分钟前
俊逸吐司完成签到 ,获得积分10
3分钟前
风吹麦浪的应助被时之王者采纳,获得10
3分钟前
优雅的树叶完成签到,获得积分10
3分钟前
昴星引路完成签到 ,获得积分10
3分钟前
含蓄的芝麻完成签到,获得积分10
3分钟前
3分钟前
STEAM完成签到,获得积分10
3分钟前
STEAM发布了新的文献求助20
4分钟前
Monica张完成签到 ,获得积分10
4分钟前
Aboo完成签到,获得积分10
4分钟前
尊敬康乃馨完成签到,获得积分10
4分钟前
乐乐的应助被STEAM采纳,获得10
4分钟前
紧张的幼蓉完成签到,获得积分10
4分钟前
5分钟前
5分钟前
文静飞松完成签到,获得积分10
5分钟前
修渊完成签到 ,获得积分10
5分钟前
温暖的大船完成签到,获得积分10
5分钟前
波爷完成签到,获得积分10
5分钟前
科研通AI6.3的应助被amiee采纳,获得10
6分钟前
lianxin完成签到 ,获得积分10
6分钟前
ABC完成签到 ,获得积分10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577354
关于积分的说明 21852358
捐赠科研通 7788708
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560092
邀请新用户注册赠送积分活动 2482902